2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2614

The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis
Abstract Number: 2616

The Effect of Smoking on Response to Tumor Necrosis Factor-Alpha Inhibitor Treatment in Ankylosing Spondylitis Patients: Results from the Turkbio Registry
Abstract Number: 2615

The Effect of Smoking on Response to Tumour Necrosis Factor-Alpha Inhibitor Treatment in Psoriatic Arthritis Patients: Results from the Turkbio Registry
Abstract Number: 2153

The Effect of Socioeconomic Status on Treatment Outcomes in Lupus Nephritis: Private Versus Public Insurance
Abstract Number: 256

The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Abstract Number: 2401

The Effects of a Gluten-Free Diet in Juvenile Idiopathic Arthritis – a Pilot Study
Abstract Number: 807

The Effects of DNA Methylation on Differential Expression in Dermal Fibroblasts from African-American Patients with Systemic Sclerosis
Abstract Number: 1148

The Effects of Physical Activity on Bone Density of High School Girls: A Prospective Study
Abstract Number: 2788

The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-Induction for Treatment of Severe ANCA-Associated Vasculitis
Abstract Number: 1879

The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study
Abstract Number: 997

The Effects of the Jak-Stat Signal Pathway Inhibition on Collagen Biosynthesis in Fibroblast Cell Culture
Abstract Number: 2532

The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry
Abstract Number: 2313

The Efficacy of Denosumab for Prevention of Osteoporotic Fractures in Patients with Connective Tissue Diseases Receiving Very High Doses of Glucocorticoid
Abstract Number: 173

The Efficacy of Treatment with Low Dose Aspirin and Low Molecular Weight Heparin in Pregnant Women with Criteria Anti-Phospholipid Antibodies
Abstract Number: 1543

The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].